Melanotan 2 and tanning: what the research actually shows

What did @dereklifts2 actually say?

Derek walked through the basic pharmacology of melanotan 2, a synthetic peptide analog of alpha-melanocyte stimulating hormone, noting it was developed in the 1990s in Arizona and works by stimulating melanocortin receptors. He correctly named four receptor subtypes (MCR-1, 3, 4, and 5), assigned functions to each, and flagged mole darkening as a major safety concern. He also disclosed he personally avoids MT2 because of his moles, and recommended dermatologist check-ins. He gave loading dose ranges of 0.1 to 0.25 mg every other day, then corrected himself mid-sentence to call these "microgram ranges," which is where things get confusing. Credit where it's due: he mentioned side effects upfront instead of burying them, which is more than most peptide influencers do.

Does the science back this up?

Partially, yes. The receptor biology is largely accurate, but the clinical evidence for MT2 in humans is thin, contested, and largely stopped at early-phase trials. Most of what's cited in peptide communities comes from animal studies or small human trials with significant methodological problems.

Melanotan 2 was indeed developed at the University of Arizona in the early 1990s by researchers including Victor Hruby and Mac Hadley, with early work published in journals like the Journal of Medicinal Chemistry. The compound does bind MC1R (driving melanogenesis), MC3R and MC4R (involved in energy balance and sexual function), and MC5R (linked to exocrine gland activity including sebaceous glands). A 2000 study by Hadley et al. in Peptides confirmed dose-dependent tanning responses in human subjects, but the trial was small and not designed to assess long-term safety. The MC4R-mediated sexual arousal effect has been documented, most notably in the development of bremelanotide (PT-141), a pharmaceutical cousin. However, calling MT2 a tool for appetite regulation or energy production based on MCR-3 and MCR-4 activity in humans overstates what the human data actually shows.

What did they get wrong (or right)?

The receptor numbering error is worth flagging. Derek said MT2 stimulates MCR-1-3-4-5, skipping MC2R. That is actually correct since MT2 does not have meaningful affinity for MC2R (the ACTH receptor), so the omission is accurate, not a mistake.

The dosing correction is the real problem. He said "0.1 to 0.25 mgs" and then said "yes, I'm talking in the microgram ranges." These are not the same thing. 0.25 mg is 250 micrograms. If he meant to say doses are in the microgram range generally, those numbers are still in the hundreds of micrograms, which is consistent with some informal protocols but is not a trivial amount. The self-correction added confusion rather than clarity. This matters because MT2 is not approved by the FDA, has no standardized dosing, and the compound circulating in the gray market has no verified purity or potency. Citing any specific numbers without that context is irresponsible, even with a research disclaimer.

His warning about mole darkening was accurate and well-placed. Research by Oliveria et al. (1999, Cancer Epidemiology, Biomarkers and Prevention) and subsequent dermatology literature have linked melanocortin stimulation to changes in existing nevi. The concern about potential mole growth is real, not fearmongering.

What should you actually know?

MT2 is not approved by the FDA or any major regulatory body for human use. It is sold as a "research chemical" with no quality control requirements, no standardized formulation, and no long-term human safety data. The studies that exist are mostly short-duration with small sample sizes.

The mole and melanoma risk is the most serious concern and deserves more than a passing mention. Individuals with dysplastic nevi or a personal or family history of melanoma face a potentially serious risk from any compound that upregulates melanocortin activity systemically. A 2009 case report in the British Journal of Dermatology by Gupta et al. described melanoma development in a patient using MT2, though causality cannot be confirmed from a single case. Dermatologists and oncologists broadly advise against uncontrolled use for this reason.

The sexual function effects via MC4R are real enough that a pharmaceutical version was developed into bremelanotide (Vyleesi), FDA-approved in 2019 for hypoactive sexual desire disorder in premenopausal women. That version went through clinical trials. MT2 did not.

• MT2 is not approved for human use anywhere with regulatory oversight.
• Gray market MT2 has no verified purity, and counterfeit or contaminated batches are a documented problem.
• Anyone with moles, a history of atypical nevi, or a family history of melanoma should avoid this compound entirely.
• The appetite suppression and sexual function effects are real receptor-level phenomena, but human evidence for therapeutic use is not established.
• Nausea and facial flushing are among the most commonly reported side effects in the limited human trial literature available.